- Merck expects sustainable growth across Life Science, Healthcare, and Electronics sectors, driven by innovation and AI.
- Strategic acquisitions, like Mirus Bio and Unity-SC, support growth. 2024 guidance: sales €20.7-€22.1 billion, EBITDA €5.8-€6.4 billion.
Thu Oct 17 07:01:02 -0000 2024 UTC– Merck expresses confidence in returning to sustainable growth at Capital Markets Day 2024. The company sees growth opportunities in its markets intact, with a focus on innovations driving growth in Life Science, Healthcare, and Electronics.
Merck plans to normalize capital expenditure and emphasizes strategic acquisitions as part of its growth strategy.
Medium-term growth ambitions are adjusted for each business sector, with the company confirming guidance for fiscal 2024.